Predicting antiviral treatment response in chronic hepatitis C: How accurate and how soon?

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 3, 2003, Pages 487-491

  Lee, Samuel S ^a   Abdo, Ayman ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Hepatitis C; Peginterferon; Predictability; Treatment

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; MONOTHERAPY; PREDICTION; VIRUS LOAD;

AGE FACTORS; ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; PREDICTIVE VALUE OF TESTS; SEX FACTORS;

EID: 0037338922     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg135     Document Type: Article

References (24)

1. Simmonds, P. (2001). The origin and evolution of hepatitis viruses in humans. Journal of General Virology 82, 693-712.
2. EASL International Consensus Conference on Hepatitis C. (2002). Consensus statement. Journal of Hepatology 30, 956-61.
3. Seeff, L. B. (2002). Natural history of hepatitis C. Hepatology 36, Suppl. 1, S35-46.
4. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L. et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 347, 975-82.
5. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R. et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358, 958-65.
6. Davis, G. L. (2002). Monitoring of viral levels during therapy of hepatitis C. Hepatology 36, Suppl. 1, S145-51.
7. Lee, S. S. (2003). Indicators and predictors of response to antiviral therapy in chronic hepatitis C. Alimentary Pharmacology and Therapeutics, in press.
8. Poynard, T., Marcellin, P., Lee, S. S., Niederaum, C., Minuk, G. S., Ideo, G. et al. (1998). Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352, 1426-32.
9. McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K. et al. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine 339, 1485-92.
10. Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C. et al. (1998). Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. New England Journal of Medicine 339, 1493-9.
11. Shiratori, Y., Kato, N., Yokosuka, O., Imazeki, F., Hashimoto, E., Hayashi, N. et al. (1997). Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 113, 558-66.
12. Martinot-Peignoux, M., Boyer, N., Pouteau, M., Castelnau, C., Giuily, N., Duchatelle, V. et al. (1998). Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Journal of Hepatology 29, 214-23.
13. Lindsay, K. L., Trepo, C., Heintges, T., Shiffman, M. L., Gordon, S. C., Hoefs, J. C. et al. (2001). A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34, 395-403.
14. Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M. Y., Gane, E. et al. (2000). Peginterferon alfa-2a in patients with chronic hepatitis C. New England Journal of Medicine 343, 1666-72.
15. Heathcote, E. J., Shiffman, M. L., Cooksley, W. G., Dusheiko, G. M., Lee, S. S., Balart, L. et al. (2000). Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. New England Journal of Medicine 343, 1673-80.
16. Lee, S. S., Heathcote, E. J., Reddy, K. R., Zeuzem, S., Fried, M. W., Wright, T. et al. (2002). Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). Journal of Hepatology 37, 500-6.
17. Wong, D. K., Cheung, A. M., O'Rourke, K., Naylor, C. D., Detsky, A. S. & Heathcote, J. (1993). Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Annals of Internal Medicine 119, 312-23.
18. Poynard, T., McHutchison, J. G., Goodman, Z. D., Ling, M. H. & Albrecht, J. (2000). Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 31, 211-8.
19. Marcellin, P., Benhamou, J., Heathcote, J., Bismuth, H., Desmet, V., Guardia, J. et al. (2000). A la carte interferon for hepatitis C. Hepatology 32, 678-9.
20. Bekkering, F. C., Brouwer, J. T., Hansen, B. E. & Schalm, S. W. (2001). Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. Journal of Hepatology 34, 435-40.
21. Castro, F. J., Esteban, J. I., Juarez, A., Sauleda, S., Viladomiu, L., Martell, M. et al. (2002). Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. Journal of Viral Hepatology 9, 202-7.
22. National Institute of Health. (2002). Recommendations from the National Institute of Health consensus development conference statement: management of hepatitis C. Hepatology 36, S3-20.
23. Neumann, A. U., Zeuzem, S. & Brunda, M. (2000). Rapid viral response to treatment with pegylated (40 kDa) interferon alfa-2a is strongly predictive of a sustained virological response in patients with chronic hepatitis C. Hepatology 32, 318A (abstract).
24. Magalini, A., Puoti, M., Putzolu, V., Quiros-Roldan, E., Forleo, M. A., Rossi, S. et al. (2000). Decrease of HCV-RNA after three days of daily interferon treatment is predictive of the virological response at one month. Journal of Clinical Laboratory Analysis 14, 120-4.